Stock performance snapshot and business profile

Globus Medical (GMED) is on investors’ radar after a recent pullback, with the stock showing a 1-day return of a 1.10% decline and a past month return of a 4.79% decline.

Over the past 3 months, Globus Medical has recorded a 2.47% decline, while the 1-year total return stands at 12.55%. Year to date, the stock is down 1.20%, giving investors mixed signals on short-term sentiment.

The company has a market value of about US$11.80b and focuses on healthcare solutions for musculoskeletal disorders, including spine products, orthopedic trauma solutions, hip and knee arthroplasty offerings, and various biologic and interventional therapies.

Globus Medical reports annual revenue of US$2.94b and net income of US$537.87m, with medical products accounting for all reported revenue. The United States contributes US$2.37b of sales, with US$571.34m coming from international markets.

At a share price of US$86.25, Globus Medical has recently seen weaker short term share price returns. However, the 1 year and multi year total shareholder returns remain positive, suggesting momentum has cooled after a stronger run.

If you are comparing Globus Medical with other healthcare names using robotics, it can be helpful to widen the lens and scan 31 robotics and automation stocks

With steady revenue and net income growth alongside cooling recent returns, the key question for you is whether Globus Medical at about US$86 is trading below its true potential or if the market is already pricing in future growth.

Most Popular Narrative: 21.3% Undervalued

Globus Medical's most followed narrative sees a fair value of about $109.54 per share, compared with the last close of $86.25, putting a spotlight on the gap between modeled value and the current market price.

Successful integration and synergy capture from the NuVasive and Nevro acquisitions are providing opportunities for increased cross-selling, cost efficiencies, and realization of deferred tax assets, which are expected to drive margin expansion, boost earnings, and enhance recurring cash flows in upcoming years.

Want to see what sits behind that margin story? The narrative leans on a specific mix of revenue growth, fatter profit margins, and a tighter earnings multiple. The exact blend is what makes the fair value tick.

The current fair value estimate of about $109.54 uses a discount rate of roughly 7.71%, with the model tying that valuation to assumptions around future revenue expansion, higher net margins and a lower future P/E than the broader US Medical Equipment industry. Compared with the latest close at $86.25, this narrative frames Globus Medical as trading at a material discount to its assessed cash flow and earnings potential over time.

Result: Fair Value of $109.54 (UNDERVALUED)

However, this story could be tested if extended sales cycles for robotics or ongoing integration issues at Nevro and NuVasive weigh on revenue and margin expectations.

Another View: Market Pricing Versus Cash Flow

The community narrative sees Globus Medical trading at a discount to a modeled fair value of about $109.54, yet the SWS DCF model points to a future cash flow value of $83.72, with shares currently at $86.25. On that cash flow lens, the stock screens slightly overvalued rather than undervalued. Which perspective aligns more closely with your expectations?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Globus Medical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the optimism in these narratives really fits your view of Globus Medical? Take a close look at the underlying numbers and pressure test the positive angles for yourself, then see how they link to the 5 key rewards

Looking for more investment ideas?

If Globus Medical has caught your attention, do not stop here; widen your opportunity set with targeted stock ideas that match different goals and risk levels.

• Spot potential value opportunities before the crowd by scanning 58 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their underlying strength.
• Strengthen your portfolio core with companies that prioritize financial resilience by reviewing the solid balance sheet and fundamentals stocks screener (39 results) to see who stands out on balance sheet quality.
• Hunt for future standouts that many investors might be overlooking by checking the screener containing 25 high quality undiscovered gems with strong fundamentals and room to attract more attention over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.